title: Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89.
abstract: We evaluated the efficacy and safety of gabapentin administered as monotherapy in an 8-day, randomized, double-blind, dose-controlled, parallel-group, multicenter study comparing dosages of 300 and 3,600 mg/d gabapentin in 82 hospitalized patients whose antiepileptic medications had been discontinued for seizure monitoring. Seizures under study were complex partial seizures with or without secondary generalization. Patients exited the study if they experienced a protocol-defined exit event indicating lack of efficacy. Time to exit was significantly longer (p = 0.0001) and completion rate was significantly higher (53% versus 17%; p = 0.002) for patients receiving 3,600 mg/d gabapentin. Gabapentin was well tolerated by patients in both dosage groups, and no patients exited the study due to adverse events, despite rapid initiation of full dose within 24 hours. These results demonstrate that gabapentin has anticonvulsant activity and is well tolerated when administered as monotherapy in patients with refractory partial seizures.
authors.affiliation: Department of Neurology, University of Maryland Medical Center, Baltimore, USA.
authors.forename: G K
authors.initials: GK
authors.lastname: Bergey
authors.forename: H H
authors.initials: HH
authors.lastname: Morris
authors.forename: W
authors.initials: W
authors.lastname: Rosenfeld
authors.forename: W T
authors.initials: WT
authors.lastname: Blume
authors.forename: P E
authors.initials: PE
authors.lastname: Penovich
authors.forename: M J
authors.initials: MJ
authors.lastname: Morrell
authors.forename: D B
authors.initials: DB
authors.lastname: Leiderman
authors.forename: J G
authors.initials: JG
authors.lastname: Crockatt
authors.forename: L
authors.initials: L
authors.lastname: LaMoreaux
authors.forename: E
authors.initials: E
authors.lastname: Garofalo
authors.forename: M
authors.initials: M
authors.lastname: Pierce
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000588:Amines; D000927:Anticonvulsants / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D017029:Epilepsy, Complex Partial / Q000188:drug therapy*; D004829:Epilepsy, Generalized / Q000188:drug therapy*; D005260:Female; D000077206:Gabapentin; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid
chemical_list: D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin